Dharmalingam, M.; Yamasandhi, P.G. Nonalcoholic fatty liver disease and Type 2 diabetes mellitus. Indian J. Endocrinol. Metab. 2018, 22, Art. No: 421. DOI: 10.4103/ijem.IJEM_585_17
Boström, P.; Wu, J.; Jedrychowski, M.P.; Korde, A.; Ye, L.; Lo, J.C.; et al. A PGC1α-dependent myokine that drives browning of white fat and thermogenesis. Nature 2011, 481, 463–468. DOI: 10.1038/nature10777
Zhang, T.; Yi, Q.; Huang, W.; Feng, J.; Liu, H. New insights into the roles of Irisin in diabetic cardiomyopathy and vascular diseases. Biomed. Pharmacother. 2024, 175, Art. No: 116631. DOI: 10.1016/j.biopha.2024.116631
Hu, J.; Ke, Y.; Wu, F.; Liu, S.; Ji, C.; Zhu, X.; et al. Circulating Irisin Levels in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Gastroenterol. Res. Pract. 2020, 2020, Art. No: 8818191. DOI: 10.1155/2020/8818191
Hou, N.; Liu, Y.; Han, F.; et al. Irisin improves perivascular adipose tissue dysfunction via regulation of the heme oxygenase-1/adiponectin axis in diet-induced obese mice. J. Mol. Cell. Cardiol. 2016, 99, 188–196. DOI: 10.1016/j.yjmcc.2016.09.005
Zhang, Y.; Li, R.; Meng, Y.; et al. Irisin stimulates browning of white adipocytes through mitogen-activated protein kinase p38 MAP kinase and ERK MAP kinase signaling. Diabetes 2014, 63, 514–525. DOI: 10.2337/db13-1106
Wang, C.; Wang, L.; Li, W.; et al. Irisin has no effect on lipolysis in 3T3-L1 adipocytes or fatty acid metabolism in HepG2 hepatocytes. Endocrine 2015, 49, 90–96. DOI: 10.1007/s12020-014-0458-9
Zhang, H.J.; Zhang, X.F.; Ma, Z.M.; Pan, L.L.; Chen, Z.; et al. Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. J. Hepatol. 2013, 59, 557–562. DOI: 10.1016/j.jhep.2013.04.030
Polyzos, S.A.; Kountouras, J.; Anastasilakis, A.D.; Geladari, E.V.; Mantzoros, C.S. Irisin in patients with nonalcoholic fatty liver disease. Metabolism 2014, 63, 207–217. DOI: 10.1016/j.metabol.2013.09.013
World Health Organization. Diagnosis and management of type 2 diabetes (HEARTS-D). Geneva: World Health Organization; 2020. WHO/UCN/NCD/20.1. Available online: https://www.who.int/publications/i/item/9789240062147 (accessed on 9 August 2019).
World Health Organization. Global Physical Activity Questionnaire (GPAQ) Analysis Guide. Geneva: World Health Organization; 2016. Available online: https:// www.who.int/publications/m/item/global-physical-activity-questionnaire (accessed on 9 August 2019).
Kosmalski, M.; Drzewoski, J.; Szymczak-Pajor, I.; Zieleniak, A.; Mikołajczyk-Solińska, M.; Kasznicki, J.; Śliwińska, A. Irisin is related to non-alcoholic fatty liver disease (NAFLD). Biomedicines 2022, 10, Art. No: 2253. DOI: 10.3390/biomedicines10092253
Bazick, J.; Donithan, M.; Neuschwander Tetri, B.A.; Kleiner, D.; Brunt, E.M.; Wilson, L.; et al. Clinical model for NASH and advanced fibrosis in adult patients with diabetes and NAFLD: Guidelines for referral in NAFLD. Diabetes Care 2015, 38, 1347–1355.
Lee, J.H.; Kim, D.; Kim, H.J.; et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig. Liver Dis. 2010, 42, 503–508. DOI: 10.1016/j.dld.2009.08.002
Jiang, Z.G.; de Boer, I.H.; Mackey, R.H.; et al. Associations of insulin resistance, inflammation and liver synthetic function with very low-density finlipoprotein: The Cardiovascular Health Study. Metabolism 2016, 65, 92–99. DOI: 10.1016/j.metabol.2015.10.017
Shanaki, M.; Moradi, N.; Emamgholipour, S.; Fadaei, R.; Poustchi, H. Lower circulating irisin is associated with nonalcoholic fatty liver disease and type 2 diabetes. Diabetes Metab. Syndr. 2017, 11, S467–S472.
Choi, E.S.; Kim, M.K.; Song, M.K.; et al. Association between serum irisin levels and non-alcoholic fatty liver disease in health screen examinees. PLoS One 2014, 9, Art. No: e110680.
Mahmoodnia, L.; Sadoughi, M.; Ahmadi, A.; Kafeshani, M. Relationship between serum irisin, glycemic indices, and renal function in type 2 diabetic patients. J. Renal Inj. Prev. 2017, 6, 88–92. DOI: 10.15171/jrip.2017.17
Wen, M.S.; Wang, C.Y.; Lin, S.L.; Hung, K.C. Decrease in irisin in patients with chronic kidney disease. PLoS One 2013, 8, Art. No: e64025.
Liu, J.J.; Liu, S.; Wong, M.D.; Tan, C.S.; Tavintharan, S.; Sum, C.F.; et al. Relationship between circulating irisin, renal function and body composition in type 2 diabetes. J. Diabetes Complicat. 2014, 28, 208–213. DOI: 10.1016/j.jdiacomp.2013.09.011
Polyzos, S.A.; Kountouras, J.; Anastasilakis, A.D.; Geladari, E.V.; Mantzoros, C.S. Irisin in patients with nonalcoholic fatty liver disease. Metabolism 2014, 63, 207–217.
Ma, Y.; Wu, X.; Liu, X.; et al. Expression of irisin in liver tissue of patients with nonalcoholic fatty liver disease. J. Zhengzhou Univ. 2016, 51, 517–520.
Park, K.H.; Zaichenko, L.; Brinkoetter, M.; et al. Circulating irisin in relation to insulin resistance and the metabolic syndrome. J. Clin. Endocrinol. Metab. 2013, 98, 4899–4907.